265 related articles for article (PubMed ID: 11280758)
1. Experimental chronotherapy of mouse mammary adenocarcinoma MA13/C with docetaxel and doxorubicin as single agents and in combination.
Granda TG; Filipski E; D'Attino RM; Vrignaud P; Anjo A; Bissery MC; Lévi F
Cancer Res; 2001 Mar; 61(5):1996-2001. PubMed ID: 11280758
[TBL] [Abstract][Full Text] [Related]
2. Docetaxel chronopharmacology in mice.
Tampellini M; Filipski E; Liu XH; Lemaigre G; Li XM; Vrignaud P; François E; Bissery MC; Lévi F
Cancer Res; 1998 Sep; 58(17):3896-904. PubMed ID: 9731500
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic index by combination of adriamycin and docetaxel depends on dosing time in mice.
Tabuchi M; To H; Sakaguchi H; Goto N; Takeuchi A; Higuchi S; Ohdo S
Cancer Res; 2005 Sep; 65(18):8448-54. PubMed ID: 16166324
[TBL] [Abstract][Full Text] [Related]
4. Preclinical profile of docetaxel (taxotere): efficacy as a single agent and in combination.
Bissery MC; Vrignaud P; Lavelle F
Semin Oncol; 1995 Dec; 22(6 Suppl 13):3-16. PubMed ID: 8604451
[TBL] [Abstract][Full Text] [Related]
5. Study of dose escalation and sequence switching of administration of the combination of docetaxel and doxorubicin in advanced breast cancer.
Itoh K; Sasaki Y; Fujii H; Minami H; Ohtsu T; Wakita H; Igarashi T; Watanabe Y; Onozawa Y; Kashimura M; Ohashi Y
Clin Cancer Res; 2000 Oct; 6(10):4082-90. PubMed ID: 11051260
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel in combination chemotherapy for metastatic breast cancer.
Khayat D; Antoine E
Semin Oncol; 1997 Aug; 24(4 Suppl 13):S13-19-S13-26. PubMed ID: 9335513
[TBL] [Abstract][Full Text] [Related]
7. Effect of docetaxel on the therapeutic ratio of fractionated radiotherapy in vivo.
Mason KA; Kishi K; Hunter N; Buchmiller L; Akimoto T; Komaki R; Milas L
Clin Cancer Res; 1999 Dec; 5(12):4191-8. PubMed ID: 10632360
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel enhances the cytotoxicity of tetrahydropyranyladriamycin in a sequence-dependent manner.
Egawa T; Kubota T; Furukawa T; Otani Y; Watanabe M; Furukawa T; Kumai K; Kitajima M
Anticancer Res; 2001; 21(4A):2597-600. PubMed ID: 11724327
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel (Taxotere) in combination with anthracyclines in the treatment of breast cancer.
Nabholtz JM; North S; Smylie M; Mackey J; Au HJ; Au R; Morrish D; Salter E; Tonkin K
Semin Oncol; 2000 Apr; 27(2 Suppl 3):11-8. PubMed ID: 10810933
[TBL] [Abstract][Full Text] [Related]
11. Anticancer activity of stabilized palifosfamide in vivo: schedule effects, oral bioavailability, and enhanced activity with docetaxel and doxorubicin.
Jones B; Komarnitsky P; Miller GT; Amedio J; Wallner BP
Anticancer Drugs; 2012 Feb; 23(2):173-84. PubMed ID: 22027537
[TBL] [Abstract][Full Text] [Related]
12. Taxoids in combination with anthracyclines and other agents: pharmacokinetic considerations.
D'Incalci M; Schüller J; Colombo T; Zucchetti M; Riva A
Semin Oncol; 1998 Dec; 25(6 Suppl 13):16-20. PubMed ID: 9865687
[TBL] [Abstract][Full Text] [Related]
13. Circadian regulation of cell cycle and apoptosis proteins in mouse bone marrow and tumor.
Granda TG; Liu XH; Smaaland R; Cermakian N; Filipski E; Sassone-Corsi P; Lévi F
FASEB J; 2005 Feb; 19(2):304-6. PubMed ID: 15545298
[TBL] [Abstract][Full Text] [Related]
14. Chronotherapy and chronotoxicity of the cyclooxygenase-2 inhibitor, celecoxib, in athymic mice bearing human breast cancer xenografts.
Blumenthal RD; Waskewich C; Goldenberg DM; Lew W; Flefleh C; Burton J
Clin Cancer Res; 2001 Oct; 7(10):3178-85. PubMed ID: 11595712
[TBL] [Abstract][Full Text] [Related]
15. Dosing time dependency of doxorubicin-induced cardiotoxicity and bone marrow toxicity in rats.
To H; Ohdo S; Shin M; Uchimaru H; Yukawa E; Higuchi S; Fujimura A; Kobayashi E
J Pharm Pharmacol; 2003 Jun; 55(6):803-10. PubMed ID: 12841941
[TBL] [Abstract][Full Text] [Related]
16. Doxorubicin followed by docetaxel versus docetaxel followed by doxorubicin in the adjuvant treatment of node positive breast cancer: results of a feasibility study.
Cardoso F; Ferreira Filho AF; Crown J; Dolci S; Paesmans M; Riva A; Di Leo A; Piccart MJ
Anticancer Res; 2001; 21(1B):789-95. PubMed ID: 11299845
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel (Taxotere) plus doxorubicin-based combinations: the evidence of activity in breast cancer.
Nabholtz JM
Semin Oncol; 1999 Jun; 26(3 Suppl 9):7-13. PubMed ID: 10426453
[TBL] [Abstract][Full Text] [Related]
18. Compilation of phase I and II trial data of docetaxel and doxorubicin in the treatment of advanced breast cancer and other malignancies.
Sparano JA
Semin Oncol; 1998 Dec; 25(6 Suppl 13):10-5. PubMed ID: 9865686
[TBL] [Abstract][Full Text] [Related]
19. Doxorubicin and taxane combination regimens for metastatic breast cancer: focus on cardiac effects.
Valero V; Perez E; Dieras V
Semin Oncol; 2001 Aug; 28(4 Suppl 12):15-23. PubMed ID: 11552226
[TBL] [Abstract][Full Text] [Related]
20. Schedule dependency of antitumor activity in combination therapy with capecitabine/5'-deoxy-5-fluorouridine and docetaxel in breast cancer models.
Fujimoto-Ouchi K; Tanaka Y; Tominaga T
Clin Cancer Res; 2001 Apr; 7(4):1079-86. PubMed ID: 11309360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]